Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas

Bibliography

• The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909-18
   PubMed Web of Science ®Google Scholar
• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998;16:2780-95
   PubMed Web of Science ®Google Scholar
• Coiffier B, Brousse N, Peuchmaur M, Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). Ann Oncol 1990;1:45-50
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Gaulard P, Lepage E, Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998;92:76-82
   PubMed Web of Science ®Google Scholar
• Abouyabis AN, Shenoy PJ, Lechowicz MJ, Flowers CR. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. Leuk Lymphoma 2008;49:2099-107
   PubMed Web of Science ®Google Scholar
• Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997;89:4514-20
   PubMed Web of Science ®Google Scholar
• Rudiger T, Weisenburger DD, Anderson JR, Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002;13:140-9
   PubMed Web of Science ®Google Scholar
• Savage KJ, Chhanabhai M, Gascoyne RD, Connors JM. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15:1467-75
   PubMed Web of Science ®Google Scholar
• Armitage JO, Vose JM, Weisenburger DD. Towards understanding the peripheral T-cell lymphomas. Ann Oncol 2004;15:1447-9
   PubMed Web of Science ®Google Scholar
• Groves F, Linet M, Travis L, Devesa SS. Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000;92:1240-51
   PubMed Web of Science ®Google Scholar
• Intragumtornchai T, Rotnakkarin P, Sutcharitchan P, Wannagrairoj P. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma. Clin Lymphoma 2003;4:52-5
   PubMedGoogle Scholar
• Isobe K, Tamaru J, Harigaya K, Clinicopathological evaluation of the revised European-American classification of lymphoid neoplasms (REAL) in Japan. Leuk Lymphoma 1999;34:143-9
   PubMed Web of Science ®Google Scholar
• Lippman SM, Miller TP, Spier CM, The prognostic significance of the immunotype in diffuse large-cell lymphoma: a comparative study of the T-cell and B-cell phenotype. Blood 1988;72:436-41
   PubMed Web of Science ®Google Scholar
• Huang HQ, Peng YL, Lin XB, Clinical outcomes of 106 patients with peripheral T-cell lymphoma treated by standard CHOP regimen. Ai Zheng 2004;23(11 Suppl):1443-7
   PubMedGoogle Scholar
• Kim K, Kim WS, Jung CW, Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the Revised European-American lymphoma (REAL) classification. Eur J Cancer 2002;38:75-81
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Cid J, Salar A, Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998;9:849-55
   PubMed Web of Science ®Google Scholar
• Blystad AK, Enblad G, Kvaloy S, High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas. Bone Marrow Transplant 2001;27:711-16
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Munsell M, Yazji S, Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001;19:3766-70
   PubMed Web of Science ®Google Scholar
• Schetelig J, Fetscher S, Reichle A, Long-term disease-free survival in patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation. Haematologica 2003;88:1272-8
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Caballero MD, Gutierrez A, High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. Ann Oncol 2003;14:1768-75
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Conde E, Gutierrez A, The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma. Haematologica 2007;92(8):1067-74
   PubMed Web of Science ®Google Scholar
• Gutierrez A, Caballero MD, Perez-Manga G, Rodriguez J. Hematopoietic SCT for peripheral T-cell lymphoma. Bone Marrow Transplant 2008;42(12):773-81
   PubMed Web of Science ®Google Scholar
• Le Gouill S, Milpied N, Buzyn A, Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008;26:2264-71
   PubMed Web of Science ®Google Scholar
• Reimer P, Ruediger T, Schertlin T, Autologous stem Cell transplantation as first-line therapy in peripheral T-cell lymphomas. A prospective multicenter study. ASH Annual Meeting Abstracts 2005 2005;106(11):2074
   Google Scholar
• Coiffier B, Gisselbrecht C, Herbrecht R, LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 1989;7:1018-26
   PubMed Web of Science ®Google Scholar
• Pautier P, Devidas A, Delmer A, Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 1999;32:545-52
   PubMed Web of Science ®Google Scholar
• Reiser M, Josting A, Soltani M, T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. Leuk Lymphoma 2002;43:805-11
   PubMed Web of Science ®Google Scholar
• Tanosaki R, Kim S-W, Yamazaki S, A retrospective single institute analysis of 127 lymphoma patients who underwent allogeneic stem cell transplantation: impact on peripheral T-Cell lymphoma (PTCL) including ATLL. ASH Annual Meeting Abstracts 2006 2006;108(11):3031
   Google Scholar
• d'Amore F, Relander T, Lauritzsen G, Dose-dense induction followed by autologous stem cell transplant (ASCT) as 1st line treatment in peripheral T-cell lymphomas (PTCL) – a Phase II Study of the Nordic Lymphoma Group (NLG). ASH Annual Meeting Abstracts 2006 2006;108(11):401
   Google Scholar
• Feyler S, Prince HM, Pearce R, The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. Bone Marrow Transplant 2007;40:443-50
   PubMed Web of Science ®Google Scholar
• Wulf GG, Hasenkamp J, Jung W, Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma. Bone Marrow Transplant 2005;36:271-3
   PubMed Web of Science ®Google Scholar
• Lansigan F, Seropian S, Cooper D, Foss F. A retrospective comparison of autologous Vs. allogeneic transplantation for peripheral T-Cell lymphoma: a single institution experience. ASH Annual Meeting Abstracts 2008 2008;112(11):4392
   Google Scholar
• Rodriguez J, Caballero MD, Gutierrez A, High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy.The GEL-TAMO experience. Haematologica 2003;88:1372-7
   PubMed Web of Science ®Google Scholar
• Yang D-H, Kim WS, Kim SJ, The clinical outcomes of autologous stem cell transplantation in peripheral T cell lymphoma: from Retrospective Multicenter Study in Korea. ASH Annual Meeting Abstracts 2007 2007;110(11):1892
   Google Scholar
• Vose JM, Peterson C, Bierman PJ, Comparison of high-dose therapy and autologous bone marrow transplantation for T-cell and B-cell non-Hodgkin's lymphomas. Blood 1990;76(2):424-31
   PubMed Web of Science ®Google Scholar
• Caballero MD, Perez-Simon JA, Iriondo A, High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group. Ann Oncol 2003;14:140-51
   PubMed Web of Science ®Google Scholar
• Song KW, Mollee P, Keating A, Crump M. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. Br J Haematol 2003;120:978-85
   PubMed Web of Science ®Google Scholar
• Kewalramani T, Zelenetz AD, Teruya-Feldstein J, Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006;134:202-7
   PubMed Web of Science ®Google Scholar
• Jantunen E, Wiklund T, Juvonen E, Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey. Bone Marrow Transplant 2004;33:405-10
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol – a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025-30
   PubMed Web of Science ®Google Scholar
• Mounier N, Gisselbrecht C, Briere J, All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 2004;15:1790-7
   PubMed Web of Science ®Google Scholar
• Mercadal S, Briones J, Xicoy B, Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 2008;19:958-63
   PubMed Web of Science ®Google Scholar
• Mercadal S, Lopez-Guillermo A, Briones J, Is There a role for autologous stem-cell transplantation (ASCT) in peripheral T-Cell lymphoma (PTCL)? final results of a prospective Phase II Study from the GELCAB. ASH Annual Meeting Abstracts 2006 2006;108(11):3070
   Google Scholar
• Reimer P, Rudiger T, Geissinger E, Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27:106-13
   PubMed Web of Science ®Google Scholar
• Nademanee AP, Zain JM, Palmer J, The impact of disease status on the outcome of high-dose therapy (HDT) and autologous stem cell transplantation (ASCT) for peripheral T-cell lymphoma (PTCL). ASH Annual Meeting Abstracts 2006 2006;108(11):3060
   Google Scholar
• Kim MK, Kim S, Lee SS, Treatment of peripheral T-cell lymphoma (PTCL) with high-dose chemotherapy and autologous stem cell transplantation (ASCT). ASH Annual Meeting Abstracts 2006 2006;108(11):4682
   Google Scholar
• Rodriguez J, Conde E, Gutierrez A, Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group. Eur J Haematol 2007;79:32-8
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Caballero MD, Gutierrez A, Prolonged survival in patients with angioimmunoblastic T-Cell lymphoma (AIL) after high-dose chemotherapy and autologous stem cell transplantation (ASCT). The GELTAMO Experience. ASH Annual Meeting Abstracts 2005 2005;106(11):2082
   Google Scholar
• Kyriakou C, Canals C, Goldstone A, High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome – lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008;26:218-24
   PubMed Web of Science ®Google Scholar
• Corradini P, Tarella C, Zallio F, Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20:1533-8
   PubMed Web of Science ®Google Scholar
• Gallamini A, Stelitano C, Calvi R, Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood 2004;103:2474-9
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Conde E, Gutierrez A, The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish lymphoma and autologous transplantation Group experience. Ann Oncol 2007;18:652-7
   PubMed Web of Science ®Google Scholar
• Repp R, Gunther A, Schade H, BEAM-alemtuzumab followed by allogeneic SCT for the treatment of relapsed or refractory T-NHL. J Clin Oncol (Meeting Abstracts) 2008 2008;26(15_Suppl):8552
   Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Cheung MM, Chan JK, Lau WH, Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol 1998;16:70-7
   PubMed Web of Science ®Google Scholar
• Siegert W, Agthe A, Griesser H, Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med 1992;117:364-70
   PubMed Web of Science ®Google Scholar
• Sonnen R, Schmidt WP, Muller-Hermelink HK, Schmitz N. The International prognostic index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol 2005;129:366-72
   PubMed Web of Science ®Google Scholar
• Reimer P, Ruediger T, Weissinger F, Different outcome for angioimmunoblastic T-Cell lymphoma (AIL) and peripheral T-Cell lymphoma unspecified (PTCL-U) following upfront autologous stem cell transplantation. ASH Annual Meeting Abstracts 2006 2006;108(11):5431
   Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002-6
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Arkenau HT, Chong G, Cunningham D, Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 2007;92:271-2
   PubMed Web of Science ®Google Scholar
• Rodriguez CO Jr, Stellrecht CM, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 2003;102:1842-8
   PubMed Web of Science ®Google Scholar
• Thompson MA, Pro B, Sarris A, Results of a Phase II Study of 506U78 (Nelarabine) in refractory indolent B-Cell or peripheral T-Cell Lymphoma. Blood 2005 2005;106(11):2681
   Google Scholar
• Tsimberidou AM, Giles F, Duvic M, Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer 2004;100:342-9
   PubMed Web of Science ®Google Scholar
• Kim JG, Sohn SK, Chae YS, CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas. Cancer Chemother Pharmacol 2006;58:35-9
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-41
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Kloess M, Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-33
   PubMed Web of Science ®Google Scholar
• Sieniawski M, Angamuthu N, Boyd K, Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010;115:3664-70
   PubMed Web of Science ®Google Scholar
• Foss F, Sjak-Shie N, Goy A, Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-cell lymphomas (PTCL), the CONCEPT Trial. ASH Annual Meeting Abstracts 2007 2007;110(11):3449
   Google Scholar
• Gallamini A, Zaja F, Patti C, Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL prospective multicenter trial. Blood 2007;110:2316-23
   PubMed Web of Science ®Google Scholar
• Gallamini A, Zaja F, Gargantini L, CHOP Chemotherapy plus campath-1H (CHOP-C) as first line treatment in patients with peripheral T-cell lymphoma (PTCL). ASH Annual Meeting Abstracts 2005 2005;106(11):3345
   Google Scholar
• Intragumtornchai T, Bunworasate U, Nakorn TN, Rojnuckarin P. Alemtuzumab in combination with CHOP and ESHAP as first-line treatment in peripheral T-cell lymphoma. ASH Annual Meeting Abstracts 2006 2006;108(11):4740
   Google Scholar
• Kim JS, Kim S-J, Lee HW, A Pilot Study of alemtuzumab plus combination chemotherapy for newly diagnosed patients with peripheral T-cell lymphomas. ASH Annual Meeting Abstracts 2006 2006;108(11):4717
   Google Scholar
• Weidmann E, Hess G, Krause SW, A Phase II immunochemotherapy Study with alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas. ASH Annual Meeting Abstracts 2006 2006;108(11):2721
   Google Scholar
• Mounier N, Simon D, Haioun C, Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2002;20:1426-7
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-94
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-86
   PubMed Web of Science ®Google Scholar
• Popplewell L, Pro B, Jacobsen E, Stem cell transplant (SCT) and pralatrexate therapy: outcome of patients with relapsed or refractory peripheral T-cell lymphoma who received SCT prior to or following pralatrexate therapy. ASH Annual Meeting Abstracts 2009 2009;114(22):3420
   Google Scholar
• O'Leary HM, Savage KJ, Toze CL, Allogeneic stem cell transplantation as treatment for relapsed and high-risk peripheral T-cell lymphoma. ASH Annual Meeting Abstracts 2007 2007;110(11):3040
   Google Scholar
• Hamadani M, Awan FT, Elder P, Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. Biol Blood Marrow Transplant 2008;14:480-3
   PubMed Web of Science ®Google Scholar
• Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009:523-31
   Google Scholar
• Bang SM, Kim YK, Park YH, High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma. Leuk Lymphoma 2005;46:1599-604
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Mercadal S, Briones J, Intensive chemotherapy (High-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation (ASCT) in previously untreated patients with peripheral T-cell lymphoma (PTCL). Results of a prospective phase II study from the GELCAB. ASH Annual Meeting Abstracts 2005 2005;106(11):2077
   Google Scholar
• Jantunen E, Itala M, Juvonen E, Autologous stem cell transplantation in elderly (> 60 years) patients with non-Hodgkin's lymphoma: a nation-wide analysis. Bone Marrow Transplant 2006;37:367-72
   PubMed Web of Science ®Google Scholar
• Smith SD, Sweetenham JW, Rybicki L, Disappointing outcomes of peripheral T Cell lymphoma after autologous stem cell transplantation. ASH Annual Meeting Abstracts 2006 2006;108(11):5428
   Google Scholar
• Chen AI, McMillan A, Negrin RS, Long term results of autologous hematopoietic cell transplantation (AHCT) for peripheral T cell lymphoma: The stanford experience. ASH Annual Meeting Abstracts 2007 2007;110(11):1906
   Google Scholar
• Corradini P, Dodero A, Zallio F, Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004;22:2172-6
   PubMed Web of Science ®Google Scholar